Global and China Chimeric Antigen Receptor (CAR)-T Cell Therapy Dynamic Monitoring and Future Investment Report 2023
Global and China Chimeric Antigen Receptor (CAR)-T Cell Therapy Dynamic Monitoring and Future Investment Report 2023
The Chimeric Antigen Receptor (CAR)-T Cell Therapy study provides a comprehensive overview of safety standards, market penetration, and innovation pipelines across major economies.
Exclusive deal : 20% Instant discount on Direct purchases! Don't wait—claim your discount today!
The report aims at estimating the market size and future growth potential of Chimeric Antigen Receptor (CAR)-T Cell Therapy market across different segments such as type, application and geography. The base year considered for the study is 2022, and the market size is forecast from 2023 to 2029.
The global Chimeric Antigen Receptor (CAR)-T Cell Therapy market size in 2022 is 2190.0 million US dollars, and it is expected to be XX million US dollars by 2029, with a compound annual growth rate of 11.80% expected in 2023-2029.
MARKET COMPETITIVE LANDSCAPE:
The main players in the Chimeric Antigen Receptor (CAR)-T Cell Therapy market include Autolus Therapeutics (U.K), CARsgen Therapeutics Co.Ltd. (U.K), Juno Therapeutics, Inc.(U.S), Sorrento Therapeutics, Inc. (U.S), and bluebird bio, Inc. (U.S). The share of the top 3 players in the Chimeric Antigen Receptor (CAR)-T Cell Therapy market is XX%.
REGION SHARE:
The report covers the market size information of North America, Europe, Asia Pacific, Latin America, Middle East and Africa, and North America accounted for XX%, Europe accounted for XX% of Chimeric Antigen Receptor (CAR)-T Cell Therapy market, and Asia Pacific accounted for XX%.
SEGMENT OVERVIEW:
The report segments the market by Type and Application. Abecma accounted for XX% of Chimeric Antigen Receptor (CAR)-T Cell Therapy market in 2022. Breyanzi share of XX%.
Acute Lymphocytic Leukemia accounted for XX% of the Chimeric Antigen Receptor (CAR)-T Cell Therapy market in 2022. Chronic Lymphocytic Leukemia accounts for XX%.
The research methodology used to estimate and forecast the Chimeric Antigen Receptor (CAR)-T Cell Therapy market begins by capturing data on key market player revenues through secondary research. The bottom-up procedure has been employed to arrive at the overall market size, by considering the revenue of key players in the market. After arriving at the overall market size, the total market has been split into several segments and sub-segments, which has been verified through primary research by conducting extensive interviews with key people such as industry experts, executives. This data triangulation and market breakdown procedures have been employed to complete the overall market engineering process and arrive at the exact statistics for segments and sub-segments.
This report provides the integrated ecosystem of the Chimeric Antigen Receptor (CAR)-T Cell Therapy market which offers holistic view of current demand and vendor side market. The research study answers several significant questions, primarily which market segments to focus on in next two to five years to prioritize factors such as resource effort, and investment.
Key Target audience:
Chimeric Antigen Receptor (CAR)-T Cell Therapy Manufacturers and Suppliers
Research and Development (R&D) Companies
Business Research and Consulting Service Providers
Research Organizations
Academic Centers and Universities Associations and Industrial Bodies
Technology Investors
The life sciences industry grows and continues to advance, driving innovation and improving healthcare outcomes for individuals around the world.
Artificial Intelligence (AI) and Machine Learning (ML): AI and ML technologies are increasingly being employed in life sciences research and development. They aid in drug discovery, optimizing clinical trials, analyzing vast amounts of biological data, and identifying patterns that can lead to breakthroughs in understanding diseases and developing new therapies.
Digital Health Technologies: Digital health technologies have seen rapid growth, especially in areas like telemedicine, wearable devices, and mobile health applications. These technologies enable remote patient monitoring, facilitate better healthcare access, and empower individuals to manage their health more effectively.
Wearable Devices and Remote Monitoring: Wearable devices, such as smartwatches and fitness trackers, have become more sophisticated, enabling continuous monitoring of vital signs and health parameters. These devices offer opportunities for early detection of health issues and improved management of chronic conditions.
Market Data Breakdown by Regions
North America
United States
Canada
China
Asia Pacific (Excluding China)
Japan
Korea
Southeast Asia
India
Australia
EMEA
Europe
Germany
France
UK
Italy
Russia
Nordic
Middle East
Africa
Latin America
Brazil
Argentina
Mexico
Some prominent players in the market includes:
Autolus Therapeutics (U.K)
CARsgen Therapeutics Co.Ltd. (U.K)
Juno Therapeutics, Inc.(U.S)
Sorrento Therapeutics, Inc. (U.S)
bluebird bio, Inc. (U.S)
CELGENE CORPORATION (U.S)
Eureka Therapeutics Inc. (U.S)
Avacta Life Sciences Ltd. (U.K)
Calyxt Inc.(France)
Celyad Oncology SA (Belgium)
Fortress Biotech, Inc (U.S.).
IMMUNE THERAPEUTICS, INC (U.S.)
Gilead Sciences, Inc. (U.S.)
Novartis AG (Switzerland)
Alaunos Therapeutics, Inc (U.S.).
Poseida Therapeutics, Inc. (U.S.)
Market Data Breakdown by Type
Abecma
Breyanzi
Kymriah
Tecartus
Yescarta
Others
Market Data Breakdown by Applications
Acute Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Non-Hodgkin Leukemia
Multiple Myeloma
Pancreatic Cancer
Neuroblasts, Breast Cancer
Acute Myeloid Leukemia
Hepatocellular
Carcinoma
Colorectal Cancer
Others
Table of Content
1 Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Introduction and Overview
1.1 Chimeric Antigen Receptor (CAR)-T Cell Therapy Definition
1.2 Research Purposes
1.3 Currency Rate
1.4 Report Timeline
1.5 Economic Analysis of Global Regions
1.6 Inflation Analysis
2 Chimeric Antigen Receptor (CAR)-T Cell Therapy Business Cost Analysis
2.1 Proportion of Manufacturing Cost Structure
2.1.1 Labor Cost
2.1.2 Operating Expenses
2.2 Chimeric Antigen Receptor (CAR)-T Cell Therapy Industrial Chain Analysis
3 Market Competition by Manufacturers
3.1 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue and Market Share by Manufacturer
3.2 Manufacturers Chimeric Antigen Receptor (CAR)-T Cell Therapy Production Sites, Area Served, Product Types
3.3 Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Competitive Situation and Trends
3.3.1 Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Concentration Rate
3.3.2 Global Top 5 and Top 10 Players Market Share by Revenue in 2023
3.3.3 Mergers & Acquisitions, Expansion
4 Players Profiles
4.1 Autolus Therapeutics (U.K)
4.1.1 Autolus Therapeutics (U.K) Company Profile
4.1.2 Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Overview
4.1.3 Autolus Therapeutics (U.K) Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Performance (2018-2023)
4.1.4 Autolus Therapeutics (U.K) Business Overview
4.2 CARsgen Therapeutics Co.Ltd. (U.K)
4.2.1 CARsgen Therapeutics Co.Ltd. (U.K) Company Profile
4.2.2 Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Overview
4.2.3 CARsgen Therapeutics Co.Ltd. (U.K) Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Performance (2018-2023)
4.2.4 CARsgen Therapeutics Co.Ltd. (U.K) Business Overview
4.3 Juno Therapeutics, Inc.(U.S)
4.3.1 Juno Therapeutics, Inc.(U.S) Company Profile
4.3.2 Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Overview
4.3.3 Juno Therapeutics, Inc.(U.S) Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Performance (2018-2023)
4.3.4 Juno Therapeutics, Inc.(U.S) Business Overview
4.4 Sorrento Therapeutics, Inc. (U.S)
4.4.1 Sorrento Therapeutics, Inc. (U.S) Company Profile
4.4.2 Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Overview
4.4.3 Sorrento Therapeutics, Inc. (U.S) Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Performance (2018-2023)
4.4.4 Sorrento Therapeutics, Inc. (U.S) Business Overview
4.5 bluebird bio, Inc. (U.S)
4.5.1 bluebird bio, Inc. (U.S) Company Profile
4.5.2 Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Overview
4.5.3 bluebird bio, Inc. (U.S) Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Performance (2018-2023)
4.5.4 bluebird bio, Inc. (U.S) Business Overview
4.6 CELGENE CORPORATION (U.S)
4.6.1 CELGENE CORPORATION (U.S) Company Profile
4.6.2 Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Overview
4.6.3 CELGENE CORPORATION (U.S) Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Performance (2018-2023)
4.6.4 CELGENE CORPORATION (U.S) Business Overview
4.7 Eureka Therapeutics Inc. (U.S)
4.7.1 Eureka Therapeutics Inc. (U.S) Company Profile
4.7.2 Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Overview
4.7.3 Eureka Therapeutics Inc. (U.S) Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Performance (2018-2023)
4.7.4 Eureka Therapeutics Inc. (U.S) Business Overview
4.8 Avacta Life Sciences Ltd. (U.K)
4.8.1 Avacta Life Sciences Ltd. (U.K) Company Profile
4.8.2 Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Overview
4.8.3 Avacta Life Sciences Ltd. (U.K) Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Performance (2018-2023)
4.8.4 Avacta Life Sciences Ltd. (U.K) Business Overview
4.9 Calyxt Inc.(France)
4.9.1 Calyxt Inc.(France) Company Profile
4.9.2 Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Overview
4.9.3 Calyxt Inc.(France) Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Performance (2018-2023)
4.9.4 Calyxt Inc.(France) Business Overview
4.10 Celyad Oncology SA (Belgium)
4.10.1 Celyad Oncology SA (Belgium) Company Profile
4.10.2 Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Overview
4.10.3 Celyad Oncology SA (Belgium) Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Performance (2018-2023)
4.10.4 Celyad Oncology SA (Belgium) Business Overview
4.11 Fortress Biotech, Inc (U.S.).
4.11.1 Fortress Biotech, Inc (U.S.). Company Profile
4.11.2 Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Overview
4.11.3 Fortress Biotech, Inc (U.S.). Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Performance (2018-2023)
4.11.4 Fortress Biotech, Inc (U.S.). Business Overview
4.12 IMMUNE THERAPEUTICS, INC (U.S.)
4.12.1 IMMUNE THERAPEUTICS, INC (U.S.) Company Profile
4.12.2 Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Overview
4.12.3 IMMUNE THERAPEUTICS, INC (U.S.) Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Performance (2018-2023)
4.12.4 IMMUNE THERAPEUTICS, INC (U.S.) Business Overview
4.13 Gilead Sciences, Inc. (U.S.)
4.13.1 Gilead Sciences, Inc. (U.S.) Company Profile
4.13.2 Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Overview
4.13.3 Gilead Sciences, Inc. (U.S.) Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Performance (2018-2023)
4.13.4 Gilead Sciences, Inc. (U.S.) Business Overview
4.14 Novartis AG (Switzerland)
4.14.1 Novartis AG (Switzerland) Company Profile
4.14.2 Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Overview
4.14.3 Novartis AG (Switzerland) Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Performance (2018-2023)
4.14.4 Novartis AG (Switzerland) Business Overview
4.15 Alaunos Therapeutics, Inc (U.S.).
4.15.1 Alaunos Therapeutics, Inc (U.S.). Company Profile
4.15.2 Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Overview
4.15.3 Alaunos Therapeutics, Inc (U.S.). Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Performance (2018-2023)
4.15.4 Alaunos Therapeutics, Inc (U.S.). Business Overview
4.16 Poseida Therapeutics, Inc. (U.S.)
4.16.1 Poseida Therapeutics, Inc. (U.S.) Company Profile
4.16.2 Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Overview
4.16.3 Poseida Therapeutics, Inc. (U.S.) Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Performance (2018-2023)
4.16.4 Poseida Therapeutics, Inc. (U.S.) Business Overview
5 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Historical and Forecast Market Analysis by Type
5.1 Market Size Analysis by Types
5.2 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue and Market Share by Type
5.3 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue Market Forecast by Type (2023-2029)
6 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Historical and Forecast Market Analysis by Application
6.1 Market Size Analysis by Application
6.2 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue Market Share by Application (2018-2023)
6.3 Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue Market Forecast by Application (2023-2029)
7 Global Market Growth Trends Analysis
7.1 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size & Forecast (2018-2029)
7.2 Chimeric Antigen Receptor (CAR)-T Cell Therapy Growth Trends Analysis by Regions
7.2.1 Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Regions: 2018 VS 2023 VS 2029
7.2.2 Chimeric Antigen Receptor (CAR)-T Cell Therapy Historic Revenue Market Size by Regions (2018-2023)
7.2.3 Chimeric Antigen Receptor (CAR)-T Cell Therapy Forecasted Revenue Market Size by Regions (2023-2029)
7.2.4 North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size & Forecast (2018-2029)
7.2.5 EMEA Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size & Forecast (2018-2029)
7.2.6 China Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size & Forecast (2018-2029)
7.2.7 Asia-Pacific (Excluding China) Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size & Forecast (2018-2029)
7.2.8 Latin America Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size & Forecast (2018-2029)
8 North America
8.1 North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue by Players
8.2 North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue by Types
8.3 North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue by Applications
8.4 North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Market by Countries
8.4.1 North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue by Countries (2018-2029)
8.5 North America SWOT Analysis
8.6 United States
8.7 Canada
9 China
9.1 China Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue by Players
9.2 China Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue by Types
9.3 China Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue by Applications
9.4 China SWOT Analysis
9.5 China
10 Asia Pacific (Excluding China)
10.1 Asia Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue by Players
10.2 Asia Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue by Types
10.3 Asia Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue by Applications
10.4 Asia Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Market by Countries
10.4.1 Asia Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue by Countries (2018-2029)
10.5 Asia Pacific SWOT Analysis
10.6 Japan
10.7 Korea
10.8 Southeast Asia
10.9 India
10.10 Australia
11 EMEA
11.1 EMEA Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue by Players
11.2 EMEA Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue by Types
11.3 EMEA Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue by Applications
11.4 EMEA Chimeric Antigen Receptor (CAR)-T Cell Therapy Market by Countries
11.4.1 EMEA Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue by Countries (2018-2029)
11.5 EMEA SWOT Analysis
11.6 Europe
11.6.1 Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue by Countries (2018-2029)
11.6.2 Germany
11.6.3 France
11.6.4 UK
11.6.5 Italy
11.6.6 Russia
11.6.7 Nordic
11.7 Middle East
11.8 Africa
12 Latin America
12.1 Latin America Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue by Players
12.2 Latin America Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue by Types
12.3 Latin America Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue by Applications
12.4 Latin America Chimeric Antigen Receptor (CAR)-T Cell Therapy Market by Countries
12.4.1 Latin America Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue by Countries (2018-2029)
12.5 Latin America SWOT Analysis
12.6 Brazil
12.7 Argentina
12.8 Mexico
13 Chimeric Antigen Receptor (CAR)-T Cell Therapy Industry Dynamic Analysis
13.1 Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Trends Analysis
13.2 Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Drivers Analysis
13.3 Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Challenges Analysis
13.4 Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Restraints Analysis
14 Research Findings and Conclusion
Tables & Figures:
List of Tables and Figures
Figure Chimeric Antigen Receptor (CAR)-T Cell Therapy Picture
Table Product Definition of Chimeric Antigen Receptor (CAR)-T Cell Therapy
Table Economic Analysis of Global Regions
Table Inflation Analysis
Table Labor Cost Analysis
Table Operating Expenses Analysis
Figure Chimeric Antigen Receptor (CAR)-T Cell Therapy Industrial Chain Analysis
Table Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue ($) by Manufacturer (2018-2023)
Table Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue Market Share by Manufacturer (2018-2023)
Figure Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue Market Share by Manufacturer in 2023
Table Manufacturers Chimeric Antigen Receptor (CAR)-T Cell Therapy Production Sites, Area Served, Product Types
Table Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Concentration Rate
Figure Global Top 5 and Top 10 Players Market Share by Revenue in 2023
Table Mergers & Acquisitions, Expansion Plans
Table Autolus Therapeutics (U.K) Profile
Table Product Overview
Table Autolus Therapeutics (U.K) Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross and Gross Margin (2018-2023)
Figure Autolus Therapeutics (U.K) Revenue and Growth Rate
Figure Autolus Therapeutics (U.K) Revenue Market Share 2018-2023
Table Business Overview
Table CARsgen Therapeutics Co.Ltd. (U.K) Profile
Table Product Overview
Table CARsgen Therapeutics Co.Ltd. (U.K) Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross and Gross Margin (2018-2023)
Figure CARsgen Therapeutics Co.Ltd. (U.K) Revenue and Growth Rate
Figure CARsgen Therapeutics Co.Ltd. (U.K) Revenue Market Share 2018-2023
Table Business Overview
Table Juno Therapeutics, Inc.(U.S) Profile
Table Product Overview
Table Juno Therapeutics, Inc.(U.S) Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross and Gross Margin (2018-2023)
Figure Juno Therapeutics, Inc.(U.S) Revenue and Growth Rate
Figure Juno Therapeutics, Inc.(U.S) Revenue Market Share 2018-2023
Table Business Overview
Table Sorrento Therapeutics, Inc. (U.S) Profile
Table Product Overview
Table Sorrento Therapeutics, Inc. (U.S) Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross and Gross Margin (2018-2023)
Figure Sorrento Therapeutics, Inc. (U.S) Revenue and Growth Rate
Figure Sorrento Therapeutics, Inc. (U.S) Revenue Market Share 2018-2023
Table Business Overview
Table bluebird bio, Inc. (U.S) Profile
Table Product Overview
Table bluebird bio, Inc. (U.S) Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross and Gross Margin (2018-2023)
Figure bluebird bio, Inc. (U.S) Revenue and Growth Rate
Figure bluebird bio, Inc. (U.S) Revenue Market Share 2018-2023
Table Business Overview
Table CELGENE CORPORATION (U.S) Profile
Table Product Overview
Table CELGENE CORPORATION (U.S) Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross and Gross Margin (2018-2023)
Figure CELGENE CORPORATION (U.S) Revenue and Growth Rate
Figure CELGENE CORPORATION (U.S) Revenue Market Share 2018-2023
Table Business Overview
Table Eureka Therapeutics Inc. (U.S) Profile
Table Product Overview
Table Eureka Therapeutics Inc. (U.S) Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross and Gross Margin (2018-2023)
Figure Eureka Therapeutics Inc. (U.S) Revenue and Growth Rate
Figure Eureka Therapeutics Inc. (U.S) Revenue Market Share 2018-2023
Table Business Overview
Table Avacta Life Sciences Ltd. (U.K) Profile
Table Product Overview
Table Avacta Life Sciences Ltd. (U.K) Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross and Gross Margin (2018-2023)
Figure Avacta Life Sciences Ltd. (U.K) Revenue and Growth Rate
Figure Avacta Life Sciences Ltd. (U.K) Revenue Market Share 2018-2023
Table Business Overview
Table Calyxt Inc.(France) Profile
Table Product Overview
Table Calyxt Inc.(France) Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross and Gross Margin (2018-2023)
Figure Calyxt Inc.(France) Revenue and Growth Rate
Figure Calyxt Inc.(France) Revenue Market Share 2018-2023
Table Business Overview
Table Celyad Oncology SA (Belgium) Profile
Table Product Overview
Table Celyad Oncology SA (Belgium) Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross and Gross Margin (2018-2023)
Figure Celyad Oncology SA (Belgium) Revenue and Growth Rate
Figure Celyad Oncology SA (Belgium) Revenue Market Share 2018-2023
Table Business Overview
Table Fortress Biotech, Inc (U.S.). Profile
Table Product Overview
Table Fortress Biotech, Inc (U.S.). Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross and Gross Margin (2018-2023)
Figure Fortress Biotech, Inc (U.S.). Revenue and Growth Rate
Figure Fortress Biotech, Inc (U.S.). Revenue Market Share 2018-2023
Table Business Overview
Table IMMUNE THERAPEUTICS, INC (U.S.) Profile
Table Product Overview
Table IMMUNE THERAPEUTICS, INC (U.S.) Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross and Gross Margin (2018-2023)
Figure IMMUNE THERAPEUTICS, INC (U.S.) Revenue and Growth Rate
Figure IMMUNE THERAPEUTICS, INC (U.S.) Revenue Market Share 2018-2023
Table Business Overview
Table Gilead Sciences, Inc. (U.S.) Profile
Table Product Overview
Table Gilead Sciences, Inc. (U.S.) Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross and Gross Margin (2018-2023)
Figure Gilead Sciences, Inc. (U.S.) Revenue and Growth Rate
Figure Gilead Sciences, Inc. (U.S.) Revenue Market Share 2018-2023
Table Business Overview
Table Novartis AG (Switzerland) Profile
Table Product Overview
Table Novartis AG (Switzerland) Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross and Gross Margin (2018-2023)
Figure Novartis AG (Switzerland) Revenue and Growth Rate
Figure Novartis AG (Switzerland) Revenue Market Share 2018-2023
Table Business Overview
Table Alaunos Therapeutics, Inc (U.S.). Profile
Table Product Overview
Table Alaunos Therapeutics, Inc (U.S.). Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross and Gross Margin (2018-2023)
Figure Alaunos Therapeutics, Inc (U.S.). Revenue and Growth Rate
Figure Alaunos Therapeutics, Inc (U.S.). Revenue Market Share 2018-2023
Table Business Overview
Table Poseida Therapeutics, Inc. (U.S.) Profile
Table Product Overview
Table Poseida Therapeutics, Inc. (U.S.) Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross and Gross Margin (2018-2023)
Figure Poseida Therapeutics, Inc. (U.S.) Revenue and Growth Rate
Figure Poseida Therapeutics, Inc. (U.S.) Revenue Market Share 2018-2023
Table Business Overview
Table Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Type (2023 VS 2029)
Table Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue and Market Size by Type (2018-2023)
Table Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue and Market Share by Type (2018-2023)
Table Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue Market Size Forecast by Type (2023-2029)
Table Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue Market Share Forecast by Type (2023-2029)
Figure Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Growth by {Type 1} (2018-2029)
Figure Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Growth by {Type 2} (2018-2029)
Table Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Application (2023 VS 2029)
Table Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue Market Size by Application (2018-2023)
Table Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue Market Share by Application (2018-2023)
Table Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue Market Size by Application (2023-2029)
Table Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue Market Share by Application (2023-2029)
Figure Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Growth by {Application 1} (2018-2029)
Figure Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Growth by {Application 2} (2018-2029)
Figure Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue Market Size & Forecast (2018-2029)
Table Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Regions: 2018 VS 2023 VS 2029
Table Chimeric Antigen Receptor (CAR)-T Cell Therapy Historic Revenue Market Size by Regions (2018-2023)
Table Chimeric Antigen Receptor (CAR)-T Cell Therapy Historic Revenue Market Share by Regions (2018-2023)
Table Chimeric Antigen Receptor (CAR)-T Cell Therapy Forecasted Revenue Market Size by Regions (2023-2029)
Table Chimeric Antigen Receptor (CAR)-T Cell Therapy Forecasted Revenue Market Share by Regions (2023-2029)
Figure North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size & Forecast (2018-2029)
Figure EMEA Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size & Forecast (2018-2029)
Figure China Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size & Forecast (2018-2029)
Figure Asia-Pacific (Excluding China) Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size & Forecast (2018-2029)
Figure Latin America Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size & Forecast (2018-2029)
Table North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue Share by Players 2022
Table North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue by Types (2018-2023)
Table North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue Market Share by Types (2018-2023)
Table North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue by Applications (2018-2023)
Table North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue Market Share by Applications (2018-2023)
Table North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue by Countries (2018-2029)
Table North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue Market Share by Countries (2018-2029)
Table North America SWOT Analysis
Figure United States Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue and Growth (2018-2029)
Figure Canada Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue and Growth (2018-2029)
Table China Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue Share by Players 2022
Table China Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue by Types (2018-2023)
Table China Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue Market Share by Types (2018-2023)
Table China Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue by Applications (2018-2023)
Table China Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue Market Share by Applications (2018-2023)
Table China SWOT Analysis
Figure China Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue and Growth (2018-2029)
Table Asia Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue Share by Players 2022
Table Asia Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue by Types (2018-2023)
Table Asia Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue Market Share by Types (2018-2023)
Table Asia Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue by Applications (2018-2023)
Table Asia Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue Market Share by Applications (2018-2023)
Table Asia-Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue by Countries (2018-2029)
Table Asia-Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue Market Share by Countries (2018-2029)
Table Asia Pacific SWOT Analysis
Figure Japan Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue and Growth (2018-2029)
Figure Korea Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue and Growth (2018-2029)
Figure Southeast Asia Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue and Growth (2018-2029)
Figure India Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue and Growth (2018-2029)
Figure Australia Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue and Growth (2018-2029)
Table EMEA Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue Share by Players 2022
Table EMEA Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue by Types (2018-2023)
Table EMEA Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue Market Share by Types (2018-2023)
Table EMEA Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue by Applications (2018-2023)
Table EMEA Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue Market Share by Applications (2018-2023)
Table EMEA Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue by Countries (2018-2029)
Table EMEA Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue Market Share by Countries (2018-2029)
Table EMEA SWOT Analysis
Figure Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue and Growth (2018-2029)
Table Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue by Countries (2018-2029)
Table Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue Market Share by Countries (2018-2029)
Figure Germany Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue and Growth (2018-2029)
Figure France Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue and Growth (2018-2029)
Figure UK Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue and Growth (2018-2029)
Figure Italy Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue and Growth (2018-2029)
Figure Russia Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue and Growth (2018-2029)
Figure Nordic Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue and Growth (2018-2029)
Figure Middle East Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue and Growth (2018-2029)
Figure Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue and Growth (2018-2029)
Table Latin America Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue Share by Players 2022
Table Latin America Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue by Types (2018-2023)
Table Latin America Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue Market Share by Types (2018-2023)
Table Latin America Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue by Applications (2018-2023)
Table Latin America Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue Market Share by Applications (2018-2023)
Table Latin America Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue by Countries (2018-2029)
Table Latin America Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue Market Share by Countries (2018-2029)
Table Latin America SWOT Analysis
Figure Brazil Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue and Growth (2018-2029)
Figure Argentina Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue and Growth (2018-2029)
Figure Mexico Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue and Growth (2018-2029)
Table Market Trends Analysis
Table Market Drivers Analysis
Table Market Challenges Analysis
Table Market Restraints Analysis
Research Methodology:
Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Estimation
To estimate market size and trends, we use a combination of top-down and bottom-up methods. This allows us to evaluate the market from various perspectives—by company, region, product type, and end users.
Our estimates are based on actual sales data, excluding any discounts. Segment breakdowns and market shares are calculated using weighted averages based on usage rates and average prices. Regional insights are determined by how widely a product or service is adopted in each area.
Key companies are identified through secondary sources like industry reports and company filings. We then verify revenue estimates and other key data points through primary research, including interviews with industry experts, company executives, and decision-makers.
We take into account all relevant factors that could influence the market and validate our findings with real-world input. Our final insights combine both qualitative and quantitative data to provide a well-rounded view. Please note, these estimates do not account for unexpected changes such as inflation, economic downturns, or policy shifts.
Data Source
Secondary Sources
This study draws on a wide range of secondary sources, including press releases, annual reports, non-profit organizations, industry associations, government agencies, and customs data. We also referred to reputable databases and directories such as Bloomberg, Wind Info, Hoovers, Factiva, Trading Economics, Statista, and others. Additional references include investor presentations, company filings (e.g., SEC), economic data, and documents from regulatory and industry bodies.
These sources were used to gather technical and market-focused insights, identify key players, analyze market segmentation and classification, and track major trends and developments across industries.
| Market Size |
|
|
| Market Position of Top Company |
|
|
| Qualitative Analysis |
|
|
Primary Sources
As part of our primary research, we interviewed a variety of stakeholders from both the supply and demand sides to gather valuable qualitative and quantitative insights.
On the supply side, we spoke with product manufacturers, competitors, industry experts, research institutions, distributors, traders, and raw material suppliers. On the demand side, we engaged with business leaders, marketing and sales heads, technology and innovation directors, supply chain executives, and end users across key organizations.
These conversations helped us better understand market segmentation, pricing, applications, leading players, supply chains, demand trends, industry outlook, and key market dynamics—including risks, opportunities, barriers, and strategic developments.
Key Data Information from Primary Sources
| Primary Sources | Parameters | Key Data |
| Market Segments(by Application, by Type) |
|
|
| Total Market |
|
|